Chemomab Therapeutics Ltd.
- CMMB
- NASDAQ
- Biotechnology
- Monoclonal Antibody (CM-101)
- Inflammatory/Fibrotic Disease
$1.26
Today −1.94%Quote Oct 16, 2026, 08:00 PM UTC
−54.82%over the last month
Max drawdown −57.5%From 1-month high −54.8%3 months −15.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$727.9M
Quote Oct 16
Next earnings
Nov 6
Expected, not confirmed
Latest analyst target
—
Data unavailable
Floor
$1.24
2.0% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CMMBPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
12